Antimicrobial therapy of bovine respiratory disease.
Our challenge in therapy of BRD is the selection of the appropriate therapy from antimicrobials with long-standing histories and newer compounds. The proliferation of new antimicrobials for BRD makes it difficult to justify the extralabel use of nonlabeled compounds. Evaluation of the BRD case definition and treatment population should be the first steps in selecting therapy and evaluating incidences of poor response.